Clinical trials: Headache Disorder
Chronic Migraine, Headache
Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine.
A growing body of literature on the cosmetic use of OnabotulinumtoxinA has suggested that the use of preserved saline exerts a local anesthetic effect, and reduces the procedure discomfort when used in reconstitution in lieu of…
- Trial name
- B-RECON (NCT03698409)
- Testing
- Preserved saline in reconstitution of Botox
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- State University of New York - Upstate Medical University
Migraine Headache
Treatment of Multiple Attacks of Acute Migraine (0462-025)
A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.
- Trial name
- NCT00899379
- Testing
- rizatriptan benzoate
- Volunteers
- 473 people
- Sponsor
- Organon and Co
Acute Migraine
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant).
- Trial name
- NCT04408794
- Testing
- Zavegepant (BHV-3500)
- Where
- 67 sites in United States
- Volunteers
- 974 people
- Sponsor
- Pfizer
Pain Disorders
Crossover, Single Dose Randomized, Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Oral Solution
Objectives: The objective of the study was to investigate the bioequivalence between two formulations containing ketoprofen lysine salt (KLS) when administered as single oral doses in two consecutive study periods to healthy male…
- Trial name
- NCT02350296
- Testing
- KSL 40 mg, OKi® 80 mg
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dompé Farmaceutici S.p.A
Migraine
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of lasmiditan 200 mg.
- Trial name
- NCT03076970
- Testing
- lasmiditan 200 mg, Sumatriptan
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Episodic Migraine Headache
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
The purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine.
- Trial name
- NCT02025556
- Testing
- LBR-101 High Dose, LBR-101 Low Dose
- Where
- 63 sites in United States
- Volunteers
- 297 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine, With or Without Aura
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
- Trial name
- NCT02873221
- Testing
- Ubrogepant, Usual Care
- Where
- 177 sites in United States
- Volunteers
- 1,254 people
- Sponsor
- Allergan
Migraine
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines.
- Trial name
- NCT00122278
- Testing
- Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 205 people
- Sponsor
- Montefiore Medical Center
Migraine
A Study of LY3451838 in Participants With Migraine
The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.
- Trial name
- NCT04498910
- Testing
- LY3451838
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Migraine, Migraine With Aura
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- EMERGE (NCT03901482)
- Testing
- Dihydroergotamine
- Where
- 117 sites in United States
- Volunteers
- 1,201 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraines
A Study of LY2951742 in Healthy Volunteers
To evaluate the safety and tolerability of LY2951742 given as single or multiple subcutaneous injection in healthy male subjects
- Trial name
- NCT01337596
- Testing
- LY2951742
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine, Migraine With Aura
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- SUMMIT (NCT04940390)
- Testing
- Dihydroergotamine
- Where
- 127 sites in United States
- Volunteers
- 1,591 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE I (NCT02828020)
- Testing
- Ubrogepant
- Where
- 90 sites in United States
- Volunteers
- 1,672 people
- Sponsor
- Allergan
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
- Trial name
- NCT01662492
- Testing
- Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2
- Where
- 22 sites in United States
- Volunteers
- 125 people
- Sponsor
- Allergan
Intervention
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.
- Trial name
- NCT02991430
- Testing
- active neuromodulation for episodic migraine headache
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Scion NeuroStim
Post-Traumatic Headache
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
This study will evaluate the effectiveness of Treximet when taken for post traumatic headache by measuring any change in the number of headache days or any change in a subject's ability to think following treatment with study…
- Trial name
- NCT01053507
- Testing
- sumatriptan/naproxen sodium
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cady, Roger, M.D.
Traumatic Brain Injury, Headaches Posttraumatic
Adjunct VR Pain Management in Acute Brain Injury
Severe and refractory pain after acute injury is a known-risk factor for chronic opioid use disorder. In this study, the investigators will use Virtual Reality (VR) immersion as a non-pharmacological adjunct to treat pain…
- Conditions
- Traumatic Brain Injury, Headaches Posttraumatic, Trauma, Pain, Acute
- Trial name
- NCT04356963
- Testing
- Virtual Reality Session (VR Blu), Tablet-based Session (Tablet Blu), Use of Virtual Reality Head Mounted Display without Content (VR Blank)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Maryland, Baltimore
Migraine
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
- Trial name
- EMBRACE (NCT04252742)
- Testing
- Erenumab
- Where
- 91 sites in United States, Bulgaria and 7 more
- Volunteers
- 512 people
- Sponsor
- Amgen
Migraine
Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Migraine patients are oftentimes referred for evidence based behavioral therapies to prevent migraine. Yet, at follow-up visits, they report not seeing the behavioral therapist.
- Trial name
- NCT03799211
- Testing
- Motivational Interviewing, Treatment as Usual
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- NYU Langone Health
Migraine Disorders, Sleep Disorder
Fremanezumab, Migraine and Sleep
The main goal of this study is to determine whether there is a relationship between fremanezumab's ability to prevent migraine and improved sleep quality in migraine patients (fremanezumab is a FDA-approved humanized CGRP…
- Trial name
- NCT04693533
- Testing
- Fremanezumab Prefilled Syringe [Ajovy]
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Beth Israel Deaconess Medical Center